Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
  • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
  • A61M1/91—Suction aspects of the dressing
  • A61M1/915—Constructional details of the pressure distribution manifold
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]

Definitions

• the invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to dressings for tissue treatment with negative pressure and methods of using the dressings for tissue treatment with negative pressure.
• a dressing for treating tissue can include a first film layer, a manifold, and a cover layer.
• the first film layer can include a treatment region and a sealing region around the treatment region.
• the first film layer can further include a first plurality of perforations formed through the treatment region and a second plurality of perforations formed through the sealing region.
• the second plurality of perforations can be larger than the first plurality of perforations.
• the first film layer can further include a sealing adhesive covering the sealing region on a first side of the first film layer configured to face the tissue site.
• the manifold can be disposed adjacent to a second side of the first film layer.
• the second side of the first film layer can be opposite the first side of the first film layer.
• the cover layer can include a second film layer and a cover adhesive.
• the cover layer can be disposed over the manifold and can be coupled to the second side of the first film layer around the manifold.
• the cover adhesive can be disposed adjacent to the second plurality of perforations.
• the manifold can include an open-cell foam having a thickness of between about 5 millimeters and about 10 millimeters.
• the second film layer can include a polyurethane film having a thickness of between about 20 microns and about 35 microns.
• the cover adhesive can include an acrylic adhesive having a coating weight of between about 25 grams per square meter and about 65 grams per square meter.
• the cover adhesive can be configured to extend through the second plurality of perforations from the second side of the first film layer to the first side of the first film layer.
• the treatment region can be free of adhesive such that the first side of the first film layer in the treatment region is configured to be positioned in direct contact with the tissue site.
• the first plurality of perforations can include slits arranged in a pattern.
• the second plurality of perforations can include circular openings arranged in a pattern.
• each of the first plurality of perforations can include a first open area and each of the second plurality of perforations can include a second open area that is larger than the first open area.
• the second plurality of perforations can be larger than the first plurality of perforations in at least one dimension.
• the first plurality of perforations can be configured to increase in size when the tissue site is exposed to a pressure.
• the second plurality of perforations do not change in size when exposed to the pressure.
• the second plurality of perforations can be larger in size than the first plurality of perforations when the tissue site is exposed to the pressure and when the tissue site is not exposed to the pressure.
• the dressing can further include a carrier layer releasably coupled to a side of the cover layer opposite the cover adhesive.
• the carrier layer can include a coated paper or a polymeric film.
• the system can include a dressing that can include a first film layer, a manifold, and a cover layer.
• the first film layer can include a treatment region and a sealing region around the treatment region.
• the first film layer can further include a first plurality of perforations formed through the treatment region and a second plurality of perforations formed through the sealing region.
• the second plurality of perforations can be larger than the first plurality of perforations.
• the first film layer can further include a sealing adhesive covering the sealing region on a first side of the first film layer configured to face the tissue site.
• the manifold can be disposed adjacent to a second side of the first film layer.
• the second side of the first film layer can be opposite the first side of the first film layer.
• the cover layer can include a second film layer and a cover adhesive.
• the cover layer can be disposed over the manifold and can be coupled to the second side of the first film layer around the manifold.
• the cover adhesive can be disposed adjacent to the second plurality of perforations.
• the system can also include a negative-pressure source configured to be fluidly coupled to the tissue site through the cover.
• the second film layer can be coated with a pressure-sensitive adhesive on a side of the second film layer configured to face the tissue site.
• the carrier layer, the first film layer, the manifold, and the second film layer can be assembled in a stacked relationship with the first film layer and the second film layer enclosing the manifold.
• the manifold can be aligned with the treatment region.
• the pressure-sensitive adhesive and the sealing region can be configured to face the tissue site and at least some of the pressure-sensitive adhesive can be exposed through the plurality of holes.
• the carrier layer can be laminated to the second film layer on a side of the second film layer opposite the pressure-sensitive adhesive.
• a negative-pressure source can be configured to be fluidly coupled to the tissue site through the aperture, the manifold, and the plurality of slits.
• the sealing adhesive is not disposed on the treatment region.
• the sealing adhesive can be applied in a pattern to the first film layer.
• the sealing adhesive can be applied in a pattern to the first film layer such that the treatment region is free of the sealing adhesive.
• the sealing adhesive can be applied in a pattern to the first film layer such that the sealing region includes the sealing adhesive, but the treatment region is free of the sealing adhesive.
• FIG. 1 is a block diagram of an example embodiment of a therapy system that can provide tissue treatment in accordance with this specification
• Figure 2 is an exploded view of an example of a dressing of the therapy system of Figure 1;
• Figure 3 is an assembly view of the dressing of Figure 2;
• Figure 4A is a top view of an example layer of the dressing of Figure 2 illustrating additional details that may be associated with some embodiments;
• Figure 4B is a bottom view of the example layer of Figure 4 illustrating additional details that may be associated with some embodiments;
• Figure 5 is a cut-away view of an illustrative embodiment of the therapy system of Figure 1 depicting an illustrative example embodiment of a dressing interface and a dressing deployed at a tissue site;
• tissue site may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that may be harvested and transplanted.
• the therapy system 100 may include a source or supply of negative pressure, such as a negative-pressure source 105, and one or more distribution components.
• a distribution component is preferably detachable and may be disposable, reusable, or recyclable.
• a dressing, such as a dressing 110, and a fluid container, such as a container 115, are examples of distribution components that may be associated with some examples of the therapy system 100.
• the dressing 110 may comprise or consist essentially of a tissue interface 120, a cover 125, or both in some embodiments.
• the therapy system 100 may also include a regulator or controller, such as a controller 130. Additionally, the therapy system 100 may include sensors to measure operating parameters and provide feedback signals to the controller 130 indicative of the operating parameters. As illustrated in Figure 1, for example, the therapy system 100 may include a first sensor 135 and a second sensor 140 coupled to the controller 130. [0044] Some components of the therapy system 100 may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy. For example, in some embodiments, the negative-pressure source 105 may be combined with the controller 130 and other components into a therapy unit 145.
• a negative-pressure supply such as the negative-pressure source 105, may be a reservoir of air at a negative pressure or may be a manual or electrically-powered device, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micropump, for example.
• Negative pressure generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures.
• a controller such as the controller 130, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negativepressure source 105.
• the controller 130 may be a microcontroller, which generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operating parameters may include the power applied to the negative -pressure source 105, the pressure generated by the negative-pressure source 105, or the pressure distributed to the tissue interface 120, for example.
• the controller 130 is also preferably configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.
• the tissue interface 120 can be generally adapted to partially or fully contact a tissue site.
• the tissue interface 120 may take many forms, and may have many sizes, shapes, or thicknesses, depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site.
• the size and shape of the tissue interface 120 may be adapted to the contours of deep and irregular shaped tissue sites. Any or all of the surfaces of the tissue interface 120 may have an uneven, coarse, or jagged profile.
• a manifold may comprise a plurality of pathways, which can be interconnected to improve distribution or collection of fluids.
• a manifold may comprise or consist essentially of a porous material having interconnected fluid pathways.
• suitable porous material that can be adapted to form interconnected fluid pathways may include cellular foam, including open-cell foam such as reticulated foam; porous tissue collections; and other porous material such as gauze or felted mat that generally include pores, edges, and/or walls.
• Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways.
• a manifold may additionally or alternatively comprise projections that form interconnected fluid pathways.
• a manifold may be molded to provide surface projections that define interconnected fluid pathways.
• the tissue interface 120 may comprise or consist essentially of reticulated foam having pore sizes and free volume that may vary according to needs of a prescribed therapy.
• reticulated foam having a free volume of at least 90% may be suitable for many therapy applications, and foam having an average pore size in a range of 400-600 microns (40- 50 pores per inch) may be particularly suitable for some types of therapy.
• the tensile strength of the tissue interface 120 may also vary according to needs of a prescribed therapy.
• the 25% compression load deflection of the tissue interface 120 may be at least 0.35 pounds per square inch, and the 65% compression load deflection may be at least 0.43 pounds per square inch.
• the tensile strength of the tissue interface 120 may be at least 10 pounds per square inch.
• the tissue interface 120 may have a tear strength of at least 2.5 pounds per inch.
• the tissue interface may be foam comprised of polyols such as polyester or polyether, isocyanate such as toluene diisocyanate, and polymerization modifiers such as amines and tin compounds.
• the tissue interface 120 may be reticulated polyurethane foam such as found in GRANUFOAMTM dressing or V.A.C. VERAFLOTM dressing, both available from 3M Company.
• the cover 125 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid.
• a polymer drape such as a polyurethane film
• Such drapes typically have a thickness in the range of 25-50 microns.
• the permeability generally should be low enough that a desired negative pressure may be maintained.
• the cover 125 may comprise, for example, one or more of the following materials: polyurethane (PU), such as hydrophilic polyurethane; cellulosics; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; silicones, such as hydrophilic silicone elastomers; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; ethylene vinyl acetate (EVA); co-polyester; and polyether block polymide copolymers.
• PU polyurethane
• PU polyurethane
• hydrophilic polyurethane such as hydrophilic polyurethane
• cellulosics such as cellulosics; hydrophilic polyamides
• the cover 125 may comprise INSPIRE® 2301 having an MVTR (upright cup technique) of 2600 g/m 2 /24 hours and a thickness of about 30 microns.
• An attachment device may be used to attach the cover 125 to an attachment surface, such as undamaged epidermis, a gasket, or another cover.
• the attachment device may take many forms.
• an attachment device may be a medically-acceptable, pressure-sensitive adhesive configured to bond the cover 125 to epidermis around a tissue site.
• some or all of the cover 125 may be coated with an adhesive, such as an acrylic adhesive, which may have a coating weight of about 25-65 grams per square meter (g.s.m .). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks.
• Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.
• the tissue interface 120 may be placed within, over, on, or otherwise proximate to a tissue site. If the tissue site is a wound, for example, the tissue interface 120 may partially or completely fill the wound, or it may be placed over the wound.
• the cover 125 may be placed over the tissue interface 120 and sealed to an attachment surface near a tissue site. For example, the cover 125 may be sealed to undamaged epidermis peripheral to a tissue site.
• the dressing 110 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 105 can reduce pressure in the sealed therapeutic environment.
• the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative pressure, for example.
• downstream typically implies a location in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure.
• upstream implies a location relatively further away from a source of negative pressure or closer to a source of positive pressure.
• inlet or outlet in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components herein.
• the fluid path may also be reversed in some applications, such as by substituting a positive-pressure source for a negativepressure source, and this descriptive convention should not be construed as limiting.
• Negative pressure applied to the tissue site through the tissue interface 120 in the sealed therapeutic environment can induce macro-strain and micro-strain in the tissue site. Negative pressure can also remove exudate and other fluid from a tissue site, which can be collected in the container 115.
• the controller 130 may receive and process data from one or more sensors, such as the first sensor 135. The controller 130 may also control the operation of one or more components of the therapy system 100 to manage the pressure delivered to the tissue interface 120.
• the controller 130 may include an input for receiving a desired target pressure and may be programmed for processing data relating to the setting and inputting of the target pressure to be applied to the tissue interface 120.
• the target pressure may be a fixed pressure value set by an operator as the target negative pressure desired for therapy at a tissue site and then provided as input to the controller 130.
• the target pressure may vary from tissue site to tissue site based on the type of tissue forming a tissue site, the type of injury or wound (if any), the medical condition of the patient, and the preference of the attending physician.
• the controller 130 can operate the negative-pressure source 105 in one or more control modes based on the target pressure and may receive feedback from one or more sensors to maintain the target pressure at the tissue interface 120.
• FIG. 2 is an exploded view of an example embodiment of the dressing 110 of Figure 1, illustrating additional details that may be associated with some embodiments in which the tissue interface 120 includes more than one layer.
• the tissue interface 120 may include a manifold 202 and a first film layer 204.
• the manifold 202 may include a first surface 206 and a second surface 208 opposite the first surface 206.
• the first film layer 204 may include a first surface 210 and a second surface 212 opposite the first surface 210.
• the first surface 210 of the first film layer 204 may couple to the second surface 208 of the manifold 202 such that the manifold 202 is stacked on top of the first film layer 204 when the dressing 110 is assembled.
• the manifold 202 may comprise or consist essentially of a manifold or manifold layer as previously described with reference to Figure 1, which provides a means for collecting or distributing fluid across the tissue interface 120 under pressure.
• the manifold 202 may be ovular or a stadium shaped manifold in some embodiments.
• the manifold 202 may be GRANUFOAMTM or an open-cell foam that may be between about 5 millimeters and about 10 millimeters thick.
• the manifold 202 may be adapted to receive negative pressure from a source, such as the negative-pressure source 105, and distnbute negative pressure through multiple apertures across the tissue interface 120, which may have the effect of collecting fluid from a tissue site and drawing the fluid toward the source.
• the fluid path may be reversed, or a secondary fluid path may be provided to facilitate delivering fluid, such as from a source of instillation solution, across the tissue interface 120.
• the first film layer 204 may comprise or consist essentially of a means for controlling or managing fluid flow.
• the first film layer 204 may include a periphery 214 that may surround an interior portion 216.
• the interior portion 216 may be symmetrically and centrally disposed in the first film layer 204.
• the periphery 214 may be a sealing region of the first film layer 204 and the interior portion 216 may be a treatment region of the first film layer 204.
• the interior portion 216 may correspond to a surface area of the manifold 202.
• a border 218 may divide or separate the interior portion 216 from the periphery 214 of the first film layer 204.
• the first film layer 204 may further include comers 220 and edges 222 that may be part of the periphery 214.
• the first film layer 204 may further include a first plurality of perforations 226 formed through the interior portion 216 and a second plurality of perforations 228 formed through the periphery 214.
• the first plurality of perforations 226 may be fluid restrictions that may be bidirectional and pressure responsive.
• the first plurality of perforations 226 can generally comprise or consist essentially of an elastic passage that can expand in response to a pressure gradient. In some embodiments, the first plurality of perforations 226 may be formed by removing material from the first film layer 204.
• the first plurality of perforations 226 may be formed by cutting through the first film layer 204, which may also deform the edges of the first plurality of perforations 226 in some embodiments. In the absence of a pressure gradient across the first plurality of perforations 226, the passages may be sufficiently small to form a seal or flow restriction, which can substantially reduce or prevent liquid flow. Additionally or alternatively, one or more of the first plurality of perforations 226 may be an elastomeric valve that is normally closed when unstrained, or not subject to negative pressure, to substantially prevent liquid flow, and can open in response to a pressure gradient.
• the first plurality of perforations 226 may comprise or consist essentially of one or more slits or slots or combinations of slits or slots in the first film layer 204.
• the first plurality of perforations 226 may comprise or consist of linear slots having a length less than 4 millimeters and a width less than 1 millimeter. The length may be at least 2 millimeters, and the width may be at least 0.4 millimeters in some embodiments. A length of about 3 millimeters and a width of about 0.8 millimeters may be particularly suitable for many applications. A tolerance of about 0. 1 millimeters may also be acceptable. Such dimensions and tolerances may be achieved with a laser cutter, for example.
• Slots of such configurations may function as imperfect valves that substantially reduce liquid flow in a normally closed or resting state.
• such slots may form a flow restriction without being completely closed or sealed.
• the slots can expand or open wider in response to a pressure gradient to allow increased liquid flow.
• the first plurality of perforations 226 may be slits or slots arranged in a pattern.
• the slits or slots may be arranged in a chevron pattern, in a grid of parallel rows and columns, or in another pattern.
• the first plurality of perforations 226 may be arranged randomly throughout the interior portion 216 of the first film layer 204.
• the second plurality of perforations 228 may be disposed through the periphery 214 of the first film layer 204.
• the second plurality of perforations 228 may be apertures or holes that may be formed by cutting or by application of local RF or ultrasonic energy, for example, or by other suitable techniques for forming an opening.
• the second plurality of perforations 228 may have a uniform distribution pattern or may be randomly distributed on the periphery 214 of the first film layer 204.
• the second plurality of perforations 228 may have many shapes, including circles, squares, stars, ovals, polygons, slits, complex curves, rectilinear shapes, triangles, for example, or may have some combination of such shapes.
• Each of the second plurality of perforations 228 may have uniform or similar geometric properties.
• each of the second plurality of perforations 228 may be circular apertures, having substantially the same diameter.
• the diameter of each of the second plurality of perforations 228 may be between about 1 millimeter to about 50 millimeters. In other embodiments, the diameter of each of the second plurality of perforations 228 may be between about 1 millimeter to about 20 millimeters.
• geometric properties of the second plurality of perforations 228 may vary.
• the diameter of the second plurality of perforations 228 may vary depending on the position of the second plurality of perforations 228.
• the second plurality of perforations 228 disposed in the comers 220 may have a diameter between about 7.75 millimeters to about 8.75 and the remainder of the second plurality of perforations 228 may have a diameter between about 9.8 millimeters to about 10.2 millimeters.
• each of the first plurality of perforations 226 may have a first open area and each of the second plurality of perforations 228 may have a second open area. Each second open area may be larger than each first open area. Similarly, each of the second plurality of perforations 228 may be larger than each of the first plurality of perforations 226 in at least one dimension. As described above, each of the first plurality of perforations 226 may be pressure responsive and thus, each of the first plurality of perforations 226 may be configured to increase in size when the tissue site is exposed to a pressure such as a negative pressure from the negativepressure source 105. In contrast, the second plurality of perforations 228 may not change in size when exposed to the pressure. Further, the second plurality of perforations 228 may be larger in size than the first plurality of perforations 226 when the tissue site is exposed to the pressure and when the tissue site is not exposed to the pressure.
• the first film layer 204 may comprise or consist essentially of a film that may provide a fluid seal with the tissue site and may have a substantially flat surface.
• the first film layer 204 may be a polyurethane film such as Pellethane® 5863-86A (Lubrizol) in some embodiments.
• the first film layer 204 may be between about 20 microns to about 35 microns thick in some embodiments.
• the first film layer 204 may further include an adhesive on the first surface 210 of the first film layer 204.
• the adhesive on the first surface 210 may adhere the first film layer 204 to the cover 125 and/or the manifold 202.
• the adhesive on the first surface 210 of the first film layer 204 may include any of the materials described above for the attachment device with reference to Figure 1.
• the dressing 110 may further include a second film layer such as the cover 125.
• the cover 125 may include a first surface 232 and a second surface 234 opposite the first surface 232.
• the second surface 234 of the cover 125 may be configured to couple to the first surface 206 of the manifold 202 of the tissue interface 120.
• the cover 125 may comprise or consist essentially of a polyurethane film such as Pellethane® 5863-86A (Lubrizol). In some embodiments, the cover 125 may have a thickness of between about 20 microns and about 35 microns.
• the dressing 110 may further include an attachment device such as the attachment device descnbed above with reference to Figure 1 or a cover adhesive or an adhesive 236.
• Discontinuities in the adhesive 236 may be provided by apertures or holes (not shown) in the adhesive 236.
• the apertures or holes in the adhesive 236 may be formed after application of the adhesive 236 or by applying the adhesive 236 in patterns on the second surface 234 of the cover 125.
• Apertures or holes in the adhesive 236 may also be sized to enhance the MVTR of the dressing 110 in some example embodiments.
• a release liner 240 may be attached to or positioned adjacent to the first film layer 204 to protect the adhesive 236 prior to use.
• the release liner 240 may also provide stiffness to assist with, for example, deployment of the dressing 110.
• the release liner 240 may be, for example, a casting paper, a film, or polyethylene.
• the release liner 240 may be a polyester material such as polyethylene terephthalate (PET), or similar polar semi-crystalline polymer.
• PET polyethylene terephthalate
• the use of a polar semi-crystalline polymer for the release liner 240 may substantially preclude wrinkling or other deformation of the dressing 110.
• the polar semi-crystalline polymer may be highly orientated and resistant to softening, swelling, or other deformation that may occur when brought into contact with components of the dressing 110, or when subjected to temperature or environmental variations, or sterilization.
• the release liner 240 may have a surface texture that may be imprinted on an adjacent layer, such as the first film layer 204.
• the release liner 240 may be ScotchpakTM Fluoropolymer Coated Release Liner (3M).
• a release agent may be disposed on a side of the release liner 240 that is configured to contact the first film layer 204.
• the release agent may be a silicone coating and may have a release factor suitable to facilitate removal of the release liner 240 by hand and without damaging or deforming the dressing 110.
• the release agent may be a fluorocarbon or a fluorosilicone, for example.
• the release liner 240 may be uncoated or otherwise used without a release agent.
• the dressing 110 may further include a carrier 242.
• the carrier 242 may include a first surface 244 and a second surface 246 opposite the first surface 244.
• the second surface 246 of the carrier 242 may be configured to couple to the first surface 232 of the cover 125.
• the earner 242 may be releasably coupled to the first surface 232 of the cover 125.
• the carrier 242 may be laminated to the first surface 232 of the cover 125.
• the carrier 242 may enable stable handling after the release liner 240 is removed from the dressing 110.
• the carrier 242 may have a first elongate portion 248 and a second elongate portion 250 connected by a connecting portion 252.
• the earner 242 may have another shape or size in some embodiments but may still provide structure for the dressing 110 after the release liner 240 is removed.
• the carrier 242 may be comprised of coated paper or film in some embodiments. Examples of carrier material may include polyethylene/vinyl acetate copolymer coated Kraft paper available from Loparex.
• Treatment of a surface wound does not include placing the dressing 110 wholly within the body or wholly under the surface of the body, such as placing a dressing within an abdominal cavity.
• the interior portion 216 of the first film layer 204 may be positioned adjacent to, proximate to, or covering a tissue site.
• the periphery 214 of the first film layer 204 may be positioned adjacent to or proximate to tissue around or surrounding the tissue site.
• the first film layer 204 may be sufficiently tacky to hold the dressing 110 in position, while also allowing the dressing 110 to be removed or re-positioned without trauma to the tissue site.
• the adhesive 236 may be pressed through the second plurality of perforations 228 to bond the dressing 110 to an attachment surface.
• the second plurality of perforations 228 at the edges 222 may permit the adhesive 236 to flow around the edges 222 for enhancing the adhesion of the edges 222 to an attachment surface.
• three of the second plurality of perforations 228 having a diameter between about 7.75 millimeters to about 8.75 millimeters may be positioned in a triangular configuration at the comers 220 to maximize the exposed surface area for the adhesive 236.
• the size and number of the second plurality of perforations 228 in the comers 220 may be adjusted as necessary, depending on the chosen geometry of the comers 220, to maximize the exposed surface area of the adhesive 236.
• the second plurality of perforations 228 at the comers 220 may be fully housed within the first film layer 204, substantially precluding fluid communication in a lateral direction exterior to the comers 220.
• the second plurality of perforations 228 at the comers 220 being folly housed within the first film layer 204 may substantially preclude fluid communication of the adhesive 236 exterior to the comers 220 and may provide improved handling of the dressing 110 during deployment at a tissue site. Further, the exterior of the comers 220 being substantially free of the adhesive 236 may increase the flexibility of the comers 220 to enhance comfort.
• the geometry and dimensions of the tissue interface 120, the cover 125, or both may vary to suit a particular application or anatomy.
• the geometry or dimensions of the tissue interface 120 and the cover 125 may be adapted to provide an effective and reliable seal against challenging anatomical surfaces, such as an elbow or heel, at and around a tissue site.
• the dimensions may be modified to increase the surface area for the first film layer 204 to enhance the movement and proliferation of epithelial cells at a tissue site and reduce the likelihood of granulation tissue in-growth.
• the dressing 110 may permit re-application or re-positioning to reduce or eliminate leaks, which can be caused by creases and other discontinuities in the dressing 110 and a tissue site.
• the ability to rectify leaks may increase the reliability of the therapy and reduce power consumption in some embodiments.
• the dressing 110 in the example of Figure 2 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 105 can reduce the pressure in the sealed therapeutic environment.
• the first film layer 204 may provide an effective and reliable seal against challenging anatomical surfaces, such as an elbow or heel, at and around a tissue site. Further, the dressing 110 may permit reapplication or re-positioning, to correct air leaks caused by creases and other discontinuities in the dressing 110, for example. The ability to rectify leaks may increase the efficacy of the therapy and reduce power consumption in some embodiments.
• the dressing interface 258 may disposed over the aperture 262 and attached to the cover 125.
• the fluid conductor 256 may be fluidly coupled to the dressing interface 258 and to the negative-pressure source 105.
• the manifold 202 may be hydrophobic to minimize retention or storage of liquid in the dressing 110.
• the manifold 202 may be hydrophilic.
• the manifold 202 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the manifold 202 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms, for example.
• An example of the manifold 202 being hydrophilic is a polyvinyl alcohol, open-cell foam such as V.A.C. WHITEFOAMTM dressing available from KCI of San Antonio, Texas.
• Other hydrophilic foams may include those made from polyether.
• Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
• the pressure differential across the first plurality of perforations 226 can dissipate, allowing the first plurality of perforations 226 to move to their resting state and prevent or reduce the rate at which exudate or other liquid from returning to the tissue site through the first film layer 204.
• Figure 3 is an assembly view of the dressing 110 of Figure 2.
• the second surface 234 of the cover 125 may be coupled to the first surface 206 of the manifold 202
• the second surface 208 of the manifold 202 may be coupled to the first surface 210 of the first film layer 204
• the second surface 212 of the first film layer 204 may be coupled to the release liner 240.
• the release liner 240 may be removed from the second surface 212 of the first film layer 204 prior to the dressing 110 being placed at a tissue site.
• the carrier 242 may be removed from the dressing 110 after the dressing is placed on a tissue site and prior to the dressing interface 258 being attached to the first surface 232 of the cover 125 of the dressing 110.
• Individual components of the dressing 110 may be bonded or otherwise secured to one another with a solvent or non-solvent adhesive, or with thermal welding, for example, without adversely affecting fluid management.
• the manifold 202 may be coupled to the border 218 of the first film layer 204 in any suitable manner, such as with a weld or an adhesive, for example.
• the cover 125, the manifold 202, the first film layer 204, or various combinations may be assembled before application or in situ.
• the cover 125 may be laminated to the manifold 202 in some embodiments.
• the first film layer 204 may also be coupled to the manifold 202 opposite the cover 125 in some embodiments.
• the dressing 110 may be provided as a single, composite dressing.
• the first film layer 204 may be coupled to the cover 125 to enclose the manifold 202, with the first film layer 204 being configured to face a tissue site.
• Figure 4A is a top view of the first film layer 204 and Figure 4B is a bottom view of the first film layer 204.
• the first film layer 204 may include the periphery 214, the interior portion 216, and the border 218 that may surround the interior portion 216 and may divide or separate the interior portion 216 from the periphery 214.
• the sealing adhesive 230 may be disposed on the second surface 212 of the first film layer 204.
• the sealing adhesive 230 may be disposed on the periphery 214 and may not be disposed on the interior portion 216 of the first film layer 204.
• the sealing adhesive 230 may be applied to the first film layer 204 such that the interior portion 216 is free from the sealing adhesive 230 and the sealing adhesive 230 surrounds each of the second plurality of perforations 228.
• the sealing adhesive 230 may be applied in a pattern to the first film layer 204.
• the sealing adhesive 230 may be applied to the periphery 214 of the second surface 212 of the first film layer 204 prior to the first plurality of perforations 226 and/or the second plurality of perforations 228 being formed through the first film layer 204.
• the sealing adhesive 230 may be a layer that may have a portion cut out that corresponds to the interior portion 216 of the first film layer 204.
• the therapy system 100 is shown at a tissue site 502.
• the tissue site 502 may extend through or otherwise involve an epidermis 504, a dermis 506, and a subcutaneous tissue 508.
• the tissue site 502 may be a sub-surface tissue site as depicted in Figure 5 that extends below the surface of the epidermis 504. Further, the tissue site 502 may be a surface tissue site (not shown) that predominantly resides on the surface of the epidermis 504, such as, for example, an incision.
• the therapy system 100 may provide therapy to, for example, the epidermis 504, the dermis 506, and the subcutaneous tissue 508, regardless of the positioning of the therapy system 100 or the type of tissue site.
• the therapy system 100 may also be utilized without limitation at other tissue sites.
• the filler material 510 may be constructed of the manifold materials described herein and may be adapted to be positioned in fluid communication with the tissue site 502 to distribute negative pressure to the tissue site 502.
• the filler material 510 may be positioned in direct contact with the tissue site 502 and between the tissue site 502 and the dressing 110. If the filler material 510 is omitted, the tissue interface 120 of the dressing 110 may be positioned in direct contact with the tissue site 502.
• the dressing 110 may be adapted to provide or distribute negative pressure from the negative-pressure source 105 of the therapy unit 145 to the tissue site 502 directly or through the filler material 510, if equipped.
• the adhesive 236 may also be in fluid communication with the edges 222 through the second plurality of perforations 228 exposed at the edges 222. Once the dressing 110 is in the desired position as shown in Figure 5A, the adhesive 236 may be pressed through the second plurality of perforations 228 to bond the dressing 110 to the epidermis 504. The second plurality of perforations 228 at the edges 222 may permit the adhesive 236 to flow around the edges 222 for enhancing the adhesion of the edges 222 to an attachment surface.
• the systems, apparatuses, and methods described herein may provide significant advantages over prior dressings.
• the dressing 110 may be thin and may be highly conformable because the tissue interface 120 may include the manifold 202 and the first film layer 204 with the sealing adhesive 230 pattern coated to the second surface 212 of the first film layer 204. Because of the thin construction, the dressing 110 may also be breathable. The dressing 110 may also be easier to lift from the tissue site 502 because of the thm edge thickness of the dressing 110.

Landscapes

• Health & Medical Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Animal Behavior & Ethology (AREA)
• Biomedical Technology (AREA)
• Vascular Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Anesthesiology (AREA)
• Hematology (AREA)
• Media Introduction/Drainage Providing Device (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=87036414

Family Applications (1)

Country Status (4)

Citations (2)

• 2023
  • 2023-05-31 EP EP23734733.1A patent/EP4536163A1/en not_active Withdrawn
  • 2023-05-31 JP JP2024571999A patent/JP2025521204A/ja active Pending
  • 2023-05-31 WO PCT/IB2023/055600 patent/WO2023237971A1/en not_active Ceased
  • 2023-05-31 CN CN202380045283.9A patent/CN119744153A/zh active Pending

Patent Citations (2)

Also Published As

Similar Documents

Legal Events